Status:

RECRUITING

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Lead Sponsor:

University of Chicago

Conditions:

Liver Diseases

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in p...

Detailed Description

Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each ...

Eligibility Criteria

Inclusion

  • Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated

Exclusion

  • \<18 yrs. of age

Key Trial Info

Start Date :

April 18 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2027

Estimated Enrollment :

1200 Patients enrolled

Trial Details

Trial ID

NCT05264051

Start Date

April 18 2022

End Date

March 1 2027

Last Update

November 14 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The University of Chicago

Chicago, Illinois, United States, 60637

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease | DecenTrialz